


Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data

Lena M Unterrainer ^{1 2 3}, Nicolas De Leiris ⁴, Marcus Unterrainer ^{1 5}, Astrid Delker ¹, Linus Hempel ¹, Zachary Ells ^{1 3}, Sophie C Kunte ^{1 2}, Josef Zahner ¹, Adrien Holzgreve ^{1 3}, Mathias J Zacherl ¹, Gabriel T Sheikh ¹, Jozefina Casuscelli ⁶, Julien Leenhardt ⁴, Kenneth J Pienta ⁷, Emmanuelle Jacquet ⁸, Mathieu Laramas ⁸, Jerome Long ⁹, Marine Faure ⁴, Ghislaine Reboulet ⁴, Channing J Paller ¹⁰, Alexis Mercier ⁴, Lilja B Solnes ^{11 12}, Kevin Kiraz ⁴, Harun Ilhan ^{1 5}, Andrei Gafita ^{11 12}, Loïc Djaileb ¹³

J Nucl Med. 2025 Jul 1;66(7):1054-1060. DOI: 10.2967/jnumed.124.269431






FIGURE 7. Sankey diagram for patient migration from SPECT RECIP + PSA to PET RECIP. PD = progressive disease; PR = partial response; SD = stable disease.

目的

PSMA標的内用療法の評価における投与後のSPECT/CTの役割について検討すること

方法

2019.4-2023.11 少なくとも2回のLu-PSMA治療を受けたmCRPC患者

・SPECT/CT: Lu-PSMA治療投与後 48時間後に撮影・PSMA-PET/CT : 治療前および2回治療後に撮影

・12週後のPSA測定

結論

Lu-PSMA治療投与後のSPECT/CT +PSAの組み合わせは、PSMA-PET/CTによるRECIPと同等の予後予測精度を示した。

勉強になった点

RECIP 1.0	
RECIP-CR	Absence of any PSMA uptake on follow-up scan
RECIP-PR	≥30% decrease in PSMA-VOL without the appearance of new lesion(s)
RECIP-PD	≥20% increase in PSMA-VOL with the appearance of new lesions
RECIP-SD	<30% decrease in PSMA-VOL with/without the appearance of new lesions or
	≥30% decrease in PSMA-VOL with the appearance of new lesion(s) or
	<20% increase in PSMA-VOL with/without the appearance of new lesions or
	≥20% increase in PSMA-VOL without the appearance of new lesions
PSA	Response: PSA ≥ 50% decrease
	Progression: PSA ≥ 25% increase
PSA + RECIP 1.0	Response: PSA ≥ 50% decrease or RECIP-PR/RECIP-CR
	Progression: PSA ≥ 25% increase or RECIP-PD



セラヨコ・トーク

- ・SPECTとPETの間で評価の変更は少ないね。
- ・実際に日本で治療後にSPECT/CTを撮ることは可能でしょうか?
- ・SPECT/CTの評価にもRECIPが使われているんですね。